Protalix Biotherapeutics Inc (PLX) Stock Analysis

Protalix Biotherapeutics Inc (PLX) is a publicly traded company in the HEALTHCARE sector. It trades at $2.00, carries a market capitalization of $170.01M, a price-to-earnings ratio of 11.11. This page summarizes the public market data, fundamentals, and frequently asked questions for PLX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

Market Sentiment

Protalix Biotherapeutics Inc currently has a Bullish sentiment score of 0.45.

About Protalix Biotherapeutics Inc

Protalix Biotherapeutics Inc. is an innovative biopharmaceutical company based in Karmiel, Israel, that specializes in the development and commercialization of recombinant therapeutic proteins through its unique ProCellEx plant cell-based expression system. Focused on addressing unmet medical needs, Protalix is advancing treatments for various conditions in markets including Israel, Brazil, and Latin America. Its commitment to biotechnology and strategic international expansion positions Prot...

GNG Research Analysis

GNG Research scores Protalix Biotherapeutics Inc (PLX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PLX.

Frequently Asked Questions

Does PLX pay dividends?

Protalix Biotherapeutics Inc (PLX) does not currently pay a regular dividend.

What is PLX's P/E ratio?

Protalix Biotherapeutics Inc has a price-to-earnings (P/E) ratio of 11.11.

What is PLX's market cap?

Protalix Biotherapeutics Inc (PLX) has a market capitalization of $170.01M with a current stock price of $2.00.